Literature DB >> 30256482

Hyperactivation of the hypothalamo-pituitary-adrenocortical axis in streptozotocin-diabetic gerbils (Gerbillus gerbillus).

Soumia Hammadi1, Owen Chan2, Mohamed Abdellali3, Maha Medjerab1, Hadjer Agoun1, Zineb Bellahreche1, Ali Khalkhal1, Yasmina Dahmani1.   

Abstract

This study was designed to investigate the HPA-axis impairment in the streptozotocin (STZ)-diabetic gerbils (Gerbillus gerbillus). Twenty-six male gerbils (body weight ~27 g) were divided into 3 groups: vehicle control (n = 10), 2 days of diabetes (n = 09) and 30 days of diabetes (n = 07). The latter 2 groups received an intraperitoneal injection of STZ (150 mg/kg of body weight). At 2 and 30 days of diabetes, streptozotocin-diabetic gerbils underwent a retro-orbital puncture for assessment of biochemical and hormonal parameters. Subsequently the animals were decapitated and the adrenal glands were removed, weighed and processed for light microscopy and stereology. Nondiabetic control gerbils that had been injected with citrate buffer were examined as a comparison. At 2 days of diabetes, STZ gerbils exhibited symptoms that are characteristic of human diabetes type 1. The adrenal gland showed significant increase in weight, associated with a larger cortex layer, hypertrophy of the fasciculate cells and a significant decrease in the nucleocytoplasmic index. These changes were associated with higher plasma ACTH and cortisol concentrations compared to nondiabetic controls. At 30 days postdiabetes, ACTH levels remained elevated, whereas cortisol levels decreased compared to the early stage of diabetes. Histological analysis revealed the existence of a band of connective tissue (collagen) that separates the cortical and medullary zones and is not present in humans or laboratory rodents, which represents a striking change seen throughout the disease. STZ-induced diabetes mellitus in Gerbillus gerbillus resulted in hyperactivation of the HPA axis in the early stages of diabetes mellitus which did not persist into the final stages of the disease, suggesting a possible reduction in adrenocortical sensitivity over time.
© 2018 The Authors. International Journal of Experimental Pathology © 2018 International Journal of Experimental Pathology.

Entities:  

Keywords:  zzm321990Gerbillus gerbilluszzm321990; HPA axis; adrenal gland; cortisol; streptozotocin; type 1 diabetes

Mesh:

Substances:

Year:  2018        PMID: 30256482      PMCID: PMC6157299          DOI: 10.1111/iep.12284

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  29 in total

1.  Abnormal regulation of adrenal function in rats with streptozotocin diabetes.

Authors:  A F De Nicola; O Fridman; E J Del Castillo; V G Foglia
Journal:  Horm Metab Res       Date:  1977-11       Impact factor: 2.936

2.  Effects of streptozotocin-induced experimental diabetes on the morphology and function of the zona fasciculata of rat adrenal cortex.

Authors:  P Rebuffat; A S Belloni; L K Malendowicz; G Mazzocchi; V Meneghelli; G G Nussdorfer
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1988

Review 3.  Mechanisms of impaired hypothalamic-pituitary-adrenal (HPA) function in diabetes: reduced counterregulatory responsiveness to hypoglycaemia.

Authors:  K Inouye; O Chan; M C Riddell; E Akirav; S G Matthews; M Vranic
Journal:  Diabetes Nutr Metab       Date:  2002-10

4.  Adrenal medullitis in type I diabetes.

Authors:  F M Brown; A M Smith; S Longway; S L Rabinowe
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

5.  Effects of L-arginine in rat adrenal cells: involvement of nitric oxide synthase.

Authors:  C B Cymeryng; L A Dada; C Colonna; C F Mendez; E J Podestá
Journal:  Endocrinology       Date:  1999-07       Impact factor: 4.736

Review 6.  [Adrenocortical insufficiency and diabetes mellitus type 1].

Authors:  Katerina Simůnková; Karel Vondra
Journal:  Cas Lek Cesk       Date:  2010

7.  Molecular regulation of the hypothalamo-pituitary-adrenal axis in streptozotocin-induced diabetes: effects of insulin treatment.

Authors:  O Chan; S Chan; K Inouye; M Vranic; S G Matthews
Journal:  Endocrinology       Date:  2001-11       Impact factor: 4.736

8.  Cholesterol metabolism in type 1 diabetes.

Authors:  Helena Gylling; Juha A Tuominen; Veikko A Koivisto; Tatu A Miettinen
Journal:  Diabetes       Date:  2004-09       Impact factor: 9.461

9.  Hyperactivation of the hypothalamo-pituitary-adrenocortical axis in streptozotocin-diabetic gerbils (Gerbillus gerbillus).

Authors:  Soumia Hammadi; Owen Chan; Mohamed Abdellali; Maha Medjerab; Hadjer Agoun; Zineb Bellahreche; Ali Khalkhal; Yasmina Dahmani
Journal:  Int J Exp Pathol       Date:  2018-08       Impact factor: 1.925

10.  Comparative study on the effects of type 1 and type 2 diabetes on structural changes and hormonal output of the adrenal cortex in male Wistar rats.

Authors:  Zohreh Elahi-Moghaddam; Morteza Behnam-Rassouli; Naser Mahdavi-Shahri; Roya Hajinejad-Boshroue; Elaheh Khajouee
Journal:  J Diabetes Metab Disord       Date:  2013-01-28
View more
  3 in total

1.  Resolvin D5 disrupts anxious- and depressive-like behaviors in a type 1 diabetes mellitus animal model.

Authors:  Felipe Fagundes Leão; Ana Paula Farias Waltrick; Waldiceu Aparecido Verri; Joice Maria da Cunha; Janaina Menezes Zanoveli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-07-19       Impact factor: 3.195

2.  Hyperactivation of the hypothalamo-pituitary-adrenocortical axis in streptozotocin-diabetic gerbils (Gerbillus gerbillus).

Authors:  Soumia Hammadi; Owen Chan; Mohamed Abdellali; Maha Medjerab; Hadjer Agoun; Zineb Bellahreche; Ali Khalkhal; Yasmina Dahmani
Journal:  Int J Exp Pathol       Date:  2018-08       Impact factor: 1.925

3.  Sema3a as a Novel Therapeutic Option for High Glucose-Suppressed Osteogenic Differentiation in Diabetic Osteopathy.

Authors:  Lixia Zhang; Lili Zheng; Chong Li; Zhifang Wang; Shan Li; Lijun Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-20       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.